DV
Dividend Vision

ARAY Stock — Accuray Incorporated

Accuray Incorporated (ARAY)

Updated November 6, 2026.

ARAY is a stock. Total return is -99.6% over the past 19.7 years, 726.4 points behind SPY at 626.8%.

Accuray Incorporated designs, develops, and sells radiosurgery and radiation therapy systems for tumor treatment worldwide, including its CyberKnife robotic platform and TomoTherapy system, along with treatment planning software and professional services to hospitals and treatment facilities. The company does not currently distribute dividends. This stock may appeal to investors seeking exposure to medical device and cancer treatment technology rather than those focused on dividend income.

ARAY performance versus SPY

Total return is -99.6% over the past 19.7 years, 726.4 points behind SPY at 626.8%. Over the past year its total return — price change plus distributions reinvested — is -91.0%. Its deepest 1-year drawdown was 91.0%.

WindowTotal returnCAGR
1M-57.7%—
3M-60.7%—
6M-77.1%—
YTD-86.6%—
1Y-91.0%—
2Y CAGR—-76.70%
3Y CAGR—-65.50%
5Y CAGR—-54.40%
10Y CAGR—-31.40%
Since inception 2007-02-08 · 19.7 years-99.6%-24.50%

ARAY key facts

Asset type
Stock
Asset class
Equity
Inception date
02/08/2007
Distribution frequency
None
Last close
$0.11 (as of 2026-11-06)
Market cap
$13,138,324
Average volume
1,948,800
Beta
1.382
Payout ratio
0.0%
Forward P/E
94.34
EPS
-$0.40

How Dividend Vision calculates returns

Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.

Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology

Sources and review

Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.

Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.

ARAY risks and drawbacks

Total return has trailed SPY over the available window. The deepest 1-year drawdown on record here is 91.0%.

Who may consider ARAY — and who may not

It is a weaker fit for investors who need monthly cash flow (ARAY does not currently distribute); investors whose main goal is matching SPY total return. This is educational context, not a recommendation to buy or sell.

More on ARAY

Tagged: Healthcare.

Frequently asked questions

Does ARAY pay monthly?

No. ARAY does not currently distribute.

When does ARAY pay a dividend?

ARAY does not currently distribute.

How has ARAY performed?

Total return is -99.6% over the past 19.7 years, 726.4 points behind SPY at 626.8%. Over the past year its total return — price change plus distributions reinvested — is -91.0%. Its deepest 1-year drawdown was 91.0%.

DividendVision analysis is generated from public SEC filing data and may not capture every change. Review the original filing for complete information.